CME Group Inc (NASDAQ:CME) – Equities research analysts at Oppenheimer boosted their Q2 2020 earnings per share estimates for CME Group in a research report issued on Wednesday, February 12th. Oppenheimer analyst O. Lau now anticipates that the financial services provider will post earnings of $1.97 per share for the quarter, up from their prior forecast of $1.91. Oppenheimer currently has a “Buy” rating and a $234.00 price target on the stock. Oppenheimer also issued estimates for CME Group’s Q3 2020 earnings at $1.96 EPS, Q4 2020 earnings at $1.67 EPS and FY2020 earnings at $7.35 EPS.
CME Group (NASDAQ:CME) last posted its quarterly earnings data on Wednesday, February 12th. The financial services provider reported $1.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.54 by ($0.02). The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.16 billion. CME Group had a net margin of 40.93% and a return on equity of 9.54%. The firm’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the business earned $1.77 EPS.
A number of other analysts have also commented on CME. Credit Suisse Group initiated coverage on CME Group in a report on Monday, December 16th. They issued a “neutral” rating for the company. Deutsche Bank lifted their target price on CME Group from $245.00 to $252.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Citigroup lifted their target price on CME Group from $220.00 to $240.00 and gave the stock a “buy” rating in a report on Monday, October 21st. UBS Group lifted their target price on CME Group from $218.00 to $221.00 and gave the stock a “neutral” rating in a report on Wednesday, December 4th. Finally, Cfra lifted their target price on CME Group from $210.00 to $218.00 and gave the stock a “hold” rating in a report on Thursday. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $209.17.
CME Group stock opened at $208.31 on Friday. The firm has a market cap of $74.65 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 4.80 and a beta of 0.14. The stock has a fifty day simple moving average of $208.11 and a two-hundred day simple moving average of $208.14. CME Group has a 12 month low of $161.05 and a 12 month high of $224.91. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.14.
Several institutional investors have recently made changes to their positions in CME. Sullivan Bruyette Speros & Blaney LLC lifted its holdings in CME Group by 10.1% during the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 1,070 shares of the financial services provider’s stock worth $215,000 after buying an additional 98 shares during the period. Ally Financial Inc. acquired a new stake in CME Group during the 4th quarter worth about $1,606,000. Guardian Capital Advisors LP grew its position in CME Group by 9.0% during the 4th quarter. Guardian Capital Advisors LP now owns 2,617 shares of the financial services provider’s stock worth $533,000 after purchasing an additional 217 shares during the period. GUARDCAP ASSET MANAGEMENT Ltd grew its position in CME Group by 47.0% during the 4th quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 747,654 shares of the financial services provider’s stock worth $150,069,000 after purchasing an additional 238,923 shares during the period. Finally, Van ECK Associates Corp grew its position in CME Group by 4.4% during the 4th quarter. Van ECK Associates Corp now owns 32,598 shares of the financial services provider’s stock worth $6,543,000 after purchasing an additional 1,385 shares during the period. Institutional investors and hedge funds own 84.10% of the company’s stock.
In other news, CEO Terrence A. Duffy sold 39,309 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $202.38, for a total value of $7,955,355.42. Following the transaction, the chief executive officer now directly owns 46,684 shares in the company, valued at $9,447,907.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Martin J. Gepsman sold 1,000 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $201.16, for a total value of $201,160.00. Following the completion of the transaction, the director now owns 34,905 shares in the company, valued at $7,021,489.80. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a $3.40 annualized dividend and a dividend yield of 1.63%. This is a positive change from CME Group’s previous quarterly dividend of $0.75. CME Group’s payout ratio is presently 43.99%.
About CME Group
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.
Featured Article: Inverted Yield Curve
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.